Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares is ...

Mr. Market's bullish sentiment towards Biogen is returning. One reason for this is its strengthening position in the multiple sclerosis drugs market, thanks to Vumerity, whose sales reached $212.3 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge-based company's ...

Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates. Is now the ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1% above analysts’ consensus estimates.